Drugs / Recombinant Methionyl Human Stem Cell Factor
Recombinant Methionyl Human Stem Cell Factor
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005783 | Mar → Oct 2000 | sickle cell-hemoglobin c disease syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1 | NCT00001398 | Oct 1993 → Jun 2002 | aplastic anemia, pancytopenia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Methionyl Human Stem Cell Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001398 ↗ |
| Known as | r-metHuSCF | “Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)” NCT00001398 ↗ |
| Known as | SCF | “Recombinant-methionyl human stem cell factor (SCF) is a hematopoietic growth factor with activity on immature hematopoietic progenitor cells.” NCT00005783 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant-methionyl human stem cell factor (SCF) is a hematopoietic growth factor with activity on immature hematopoietic progenitor cells.” NCT00005783 ↗ |